-
Actavis Inc., the generic drugmaker whose merger negotiations with Valeant Pharmaceuticals International Inc. stalled over price, may deserve the industry’s second-best valuation ever in a deal.
-
U.S. court ruling allowing generic versions of AstraZeneca’s Pulmicort asthma treatment may spur 2% reduction in Teva EPS for 3 quarters and greater hit in 2014, Canaccord Genuity analysts led by Randall Stanicky wrote in e- mailed note. *Teva likely to lose royalty back to AstraZeneca *Teva reaffirmed hold, $45 pt **NOTE: AstraZeneca May Appeal U.S. Patent Ruling on Pulmicort Respules NSN MKMET76JTSEN <GO>
-
Radware Ltd. may end two years of slower sales growth as cyber attacks on U.S. lenders including Bank of America Corp. bolster demand for the Israeli company’s security software, Chief Executive Officer Roy Zisapel said.
-
EZchip Semiconductor Ltd. fell the most in three months in New York after the Israeli maker of network processors said sales will drop, joining chipmakers Texas Instruments Inc. and Infineon Technologies AG in warning demand may weaken as Europe’s sovereign-debt crisis saps growth.
-
EZchip Semiconductor Ltd. fell the most in three months in New York after the Israeli maker of network processors said sales will drop, joining chipmakers Texas Instruments Inc. and Infineon Technologies AG in warning demand may weaken as Europe’s sovereign-debt crisis saps growth.
-
Teva Pharmaceutical Industries Ltd. rose to the highest level in almost three months in Tel Aviv, as the cheapest valuation among global peers outweighed a study that showed a competitor’s drug was more effective.
-
When Sara Gibson’s head starts to tingle, she knows she’s in trouble.
-
Perrigo Co. surged the most in 18 months in New York as the largest U.S. maker of generic over- the-counter drugs reported quarterly sales that beat analyst forecasts for the first time in a year.
-
Warner Chilcott Plc offers potential acquirers the chance to buy a company that throws off more cash from selling contraceptives and colitis treatments than any specialty drugmaker in the world.
-
Perrigo Co. posted its biggest two- week gain since September 2010 after shares of the largest U.S. maker of generic over-the-counter drugs were added to the Standard & Poor’s 500 and Nasdaq 100 indexes, increasing the premium relative to the Tel Aviv-traded stock.
Rate this Page